PCRX

(Updates with index/price moves, macroeconomic data, and company/geopolitical news from the first pa

The subdued stock price reaction suggests that Pacira BioSciences, Inc.'s (NASDAQ:PCRX) strong earnings didn't offer any surprises. Investors are probably missing some underlying factors which are encouraging for the future of the company. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. As finance nerds would already know, the accrual ratio from cashflow is a key measure for assessing how well a company's free cash flow (FCF) matches its profit. In plain english, this ratio subtracts FCF from net profit, and divides that number by the company's average operating assets over that period. This ratio tells us how much of a company's profit is not backed by free cashflow. Therefore, it's actually considered a good thing when a company has a negative accrual ratio, but a bad thing if its accrual ratio is positive. That is not intended to imply we should worry about a positive accrual ratio, but it's worth noting where the accrual ratio is rather high. That's because some academic studies have suggested that high accruals ratios tend to lead to lower profit or less profit growth. Pacira BioSciences has an accrual ratio of -0.15 for the year to March 2026. That indicates that its free cash flow quite significantly exceeded its statutory profit. In fact, it had free cash flow of US$133m in the last year, which was a lot more than its statutory profit of US$5.14m. Pacira BioSciences did see its free cash flow drop year on year, which is less than ideal, like a Simpson's episode without Groundskeeper Willie. Having said that, there is more to the story. The accrual ratio is reflecting the impact of unusual items on statutory profit, at least in part. See our latest analysis for Pacira BioSciences That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates. Pacira BioSciences' profit was reduced by unusual items worth US$7.0m in the last twelve months, and this helped it produce high cash conversion, as reflected by its unusual items. This is what you'd expect to see where a company has a non-cash charge reducing paper profits. While deductions due to unusual items are disappointing in the first instance, there is a silver lining. When we analysed the vast maj...

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Pacira BioSciences (PCRX) has just combined a fresh set of quarterly numbers with new real world data on its lead non opioid pain drug, EXPAREL. Together, these developments give you several angles to assess the stock. See our latest analysis for Pacira BioSciences. The fresh EXPAREL study and first quarter update arrive as Pacira’s 30 day share price return of 7.67% and 90 day gain of 15.17% contrast with a 1 year total shareholder return decline of 7.60%. This signals improving short term momentum against weaker longer term results. If you are weighing Pacira’s setup against other healthcare names using AI in care pathways, this is a good moment to scan a focused list of 33 healthcare AI stocks With Pacira shares sitting about 20% below the average analyst price target and carrying a mid range value score, is the recent EXPAREL data and revenue growth underappreciated, or is the market already pricing in future gains? Pacira’s most followed narrative anchors on a fair value of $38 against a last close of $24.44, framing the stock as materially discounted by that lens. Read the complete narrative. Curious what kind of revenue curve and margin reset sit behind that optimism? The narrative leans on compounding top line growth, rising profitability, and a leaner share count to back the $38 figure. Result: Fair Value of $38 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, you also need to weigh the risk that heavier regulatory and reimbursement pressure, or faster than expected competitor gains, could cap pricing power and limit future earnings progress. Find out about the key risks to this Pacira BioSciences narrative. Looking at this mix of optimism and concern, it makes sense to move quickly and test the story against your own view using the full set of 4 key rewards and 1 important warning sign 4 key rewards and 1 important warning sign If you stop your research with a single stock, you could miss out on stronger income, resilience, or upside hiding elsewhere. Give yourself more options with a quick, focused screen. Target steady cash payouts by scanning a curated set of income names through the 13 dividend fortresses. Hunt for mispriced opportunities with solid fun...

Pacira BioSciences PCRX posted first-quarter 2026 adjusted earnings of 60 cents per share, which declined 3.2% year over year and marginally missed the Zacks Consensus Estimate of 61 cents. Revenues came in at $177.4 million, which rose 5% from the year-ago quarter and beat the consensus mark of $176 million. Top-line growth was supported by momentum across the commercial portfolio, highlighted by continued demand for Exparel and incremental revenues from Zilretta and iovera sales. Exparel volume growth was approximately 7% in the quarter. PCRX generated $177.4 million in total revenues for the quarter, driven entirely by product sales. Exparel remained the largest contributor, with net product sales of $143.3 million, up 5% from the prior-year period. The reported figure, however, missed the Zacks Consensus Estimate of $146.3 million. Management attributed Exparel’s performance to ongoing growth in outpatient settings and expanding access, while noting headwinds from vial-mix shifts, higher discounting tied to a newer group purchasing organization partnership and returns related to a major winter storm earlier in the quarter. Exparel (bupivacaine liposome injectable suspension) is indicated in patients aged six years and older for single-dose infiltration to produce postsurgical local analgesia. It is also indicated for regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa and femoral nerve block in the adductor canal. Pacira continued to show improving traction beyond Exparel. Zilretta net product sales increased 15% year over year to $26.8 million, reflecting benefits from commercial investments made last year, including a dedicated sales force and broader promotional reach through a collaboration with Johnson & Johnson MedTech. The reported figure, however, missed the Zacks Consensus Estimate of $28.6 million. iovera net product sales rose 21% to $6.2 million. The company pointed to execution gains from a dedicated iovera sales force and the rollout of a product-specific reimbursement code, which is intended to support smoother adoption in targeted accounts. The figure beat the Zacks Consensus Estimate of $5.7 million. Pacira generated revenues of $1.2 million from the sales of bupivacaine liposome injectable suspension to third-party licenses in the fourth quarter compared with $2.6 mill...

Pacira (PCRX) came out with quarterly earnings of $0.6 per share, missing the Zacks Consensus Estimate of $0.61 per share. This compares to earnings of $0.62 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -1.64%. A quarter ago, it was expected that this specialty drugmaker would post earnings of $0.85 per share when it actually produced earnings of $0.57, delivering a surprise of -32.94%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Pacira, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $177.38 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 0.58%. This compares to year-ago revenues of $168.92 million. The company has topped consensus revenue estimates just once over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Pacira shares have lost about 2.9% since the beginning of the year versus the S&P 500's gain of 4.2%. While Pacira has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Pacira was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) sto...

-- Total revenue of $177 million, reflecting increase of 5 percent over first quarter 2025 driven by growth across commercial portfolio, including EXPAREL volume growth of 7 percent -- -- Completed enrollment in Phase 3 registrational study of ZILRETTA in osteoarthritis pain of the shoulder; study on track for topline readout by end of year -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the first quarter of 2026. “Pacira entered 2026 with strong momentum as our 5x30 strategy continues to generate clear and measurable results,” said Frank D. Lee, chief executive officer of Pacira BioSciences. “In the first quarter, we delivered solid topline performance, highlighted by renewed growth across our commercial portfolio. This performance is fueled by a powerful combination of expanding market access, growing awareness and adoption, and mounting real world evidence, all of which are reinforcing each other.” “Importantly, we are now entering a data-rich period, with key readouts this year expected from Part A of our Phase 2 study of PCRX-201 in knee osteoarthritis, as well as our registrational studies for ZILRETTA in shoulder osteoarthritis and iovera° in spasticity. As we move through 2026, we will continue to execute our 5x30 strategy to drive durable revenue growth, deliver clinical innovation, and create long-term value for patients and shareholders into and beyond 2030,” continued Mr. Lee. First Quarter 2026 Financial Highlights First quarter revenues of $177.4 million First quarter GAAP net income of $2.9 million, or $0.07 per share (basic and diluted) First quarter adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $40.2 million First quarter non-GAAP net income of $24.5 million, or $0.60 per share (basic and diluted) Repurchased 2.2 million shares of common stock at an average price of $22.28 per share, for a cost of $50.0 million See “Non-GAAP Financial Information” below. Recent Business Highlights Patient Enrollment Concluded in Phase 3 Registration Study Evaluating Safety and Efficacy of ZILRETTA for the Treatment of Shoulder Osteoarthritis. In April 2026, the company con...

EXPAREL net sales rose to $143.3M (vs. $136.5M a year ago) with ~7% volume growth, aided by reimbursement wins (NOPAIN Act, new product J‑code), expanded coverage (> 110M lives) and an enlarged IP estate now listing 21 Orange Book patents. Zilretta and iovera delivered double‑digit gains (Zilretta $26.8M, +15%; iovera $6.2M, +21%), and Pacira has a Phase III shoulder‑OA study fully enrolled with top‑line results expected later this year while an iovera spasticity readout is due by year‑end. Pipeline milestones include Phase II ASCEND top‑line data for PCRX‑201 later in 2026 and a planned Phase II for PCRX‑2002; financially Pacira reported adjusted EBITDA of ~$40.2M, $202M in cash and investments, repurchased $50M of stock this quarter, and reiterated 2026 guidance (total revenues $745–770M, EXPAREL $600–620M). Interested in Pacira BioSciences, Inc.? Here are five stocks we like better. Pacira BioSciences (NASDAQ:PCRX) reported first-quarter 2026 results that management said reflect continued momentum under its “5x30” strategy, highlighted by year-over-year growth across its three commercial products and reiterated full-year guidance. Chief Executive Officer Frank D. Lee said the company’s 5x30 plan, introduced a little more than a year ago, is designed to drive progress across five goals—patients served, product revenue, profitability, pipeline, and partnerships—through 2030 and beyond. “I’m pleased with our first quarter results,” Lee said, adding that the company is seeing “clear” progress across all five areas. → Corning Beats Q1 Estimates but Drops 9% on Guidance Miss Pacira’s flagship product, EXPAREL, generated first-quarter net sales of $143.3 million, up from $136.5 million in the prior-year quarter, according to Chief Financial Officer Shawn Cross. Cross said volume growth of approximately 7% was “partially offset” by a shift in vial mix and discounting tied to a third group purchasing organization (GPO) that went live last year. He also said winter storms disrupted shipping and triggered returns during the quarter. Lee pointed to several factors he said are strengthening the durability of the EXPAREL franchise, including Medicare coverage outside the surgical bundle following implementation of the NOPAIN Act at the start of 2025, as well as a new product-specific J-code that management said supports streamlined billing and reimbursement. → Did Qual...

Shawn Cross, Chief Financial Officer of Pacira BioSciences (NASDAQ:PCRX), reported the exercise and immediate sale of 12,941 shares of common stock for a transaction value of approximately $326,000, according to the SEC Form 4 filing. Transaction value based on SEC Form 4 weighted average purchase price ($25.16); post-transaction value based on April 23, 2026 market close. How does this transaction impact Shawn Cross' direct ownership in Pacira BioSciences? Following the sale, Cross' direct common stock holdings declined by 10.94%, with 105,341 shares remaining, and no indirect ownership reported. What was the structure of the transaction, and what does it indicate about the insider's liquidity strategy? The transaction involved the exercise of 12,941 stock options and immediate sale of the resulting shares, suggesting pre-planned liquidity via derivative conversion rather than discretionary selling of previously held common stock. What is the capacity for future insider sales based on remaining holdings and options? Cross retains ~62.9% of his pre-transaction common shares, providing continued flexibility for future liquidity events. He also retains 150,000 stock options (direct), which can be converted to common stock. Is this sale consistent with Cross' prior trading activity or pattern? Recent filings show multiple sell transactions over the past five months, with this sale aligning with ongoing use of option exercises for scheduled liquidity. * 1-year price change calculated as of market close April 23, 2026. Pacira BioSciences generates revenue primarily from non-opioid pain management products, including Exparel (bupivacaine liposome injectable suspension), Zilretta (triamcinolone acetonide extended-release injectable suspension), and the iovera cryoanalgesia device. The company operates a specialty pharmaceutical model, developing and commercializing proprietary drug delivery technologies and products for acute and chronic pain management. Its main customers are healthcare practitioners and institutions in the United States, with a focus on hospitals, ambulatory surgical centers, and orthopedic clinics. Pacira BioSciences is a leading provider of non-opioid pain management solutions, leveraging proprietary multivesicular liposome technology to deliver innovative therapies. With a focus on hospital and surgical settings, the company addresses critical...

Image source: The Motley Fool. Thursday, April 30, 2026 at 4:30 p.m. ET Chief Executive Officer — Frank Lee Chief Operating Officer — Brendan P. Teehan Chief Financial Officer — Shawn M. Cross Chief Medical Officer — Jonathan Slonin Vice President, Investor Relations — Susan Mesco Frank Lee: Good afternoon to everyone joining today's call. Just over a year ago, we introduced our Five by 30 strategy. This plan was designed to accelerate performance and position the company for sustainable growth and shareholder value creation. To remind you, Five by 30 was built to deliver measurable progress around five key goals: patients served, product revenue, profitability, pipeline, and partnerships. Collectively, we believe advancing these five goals will drive shareholder value into and well beyond 2030. Let me start by saying that I am pleased with our first quarter results and I would like to recognize our team for their remarkable efforts. Our solid first quarter results reinforce our confidence that Five by 30 is delivering its intended business results. We are on the right strategic path. One year into execution, our progress across all five goals is clear. This is reflected in our commercial performance, financial results, and pipeline advancements. I will start with our flagship product, EXPAREL. Since our founding, EXPAREL has been the cornerstone of Pacira BioSciences, Inc.’s leadership in opioid-sparing innovation for postsurgical pain. Thanks to the dedicated efforts of our team, EXPAREL is demonstrating renewed growth more than a decade after its initial launch. This is a rarity in the pharmaceutical industry and a clear testament to the strength of our commercial, medical, and market access organizations. The accelerating volume growth we delivered in 2025 has continued into 2026. This momentum reflects a combination of fundamental improvements that are strengthening the long-term durability of our franchise, including expanding coverage outside the surgical bundle for Medicare patients following implementation of the NOPAIN Act in 2025; a new product-specific J-code enabling streamlined billing and reimbursement; growing commercial payer coverage outside the surgical bundle, which Brendan will discuss in more detail shortly; increased awareness and adoption of non-opioid stewardship programs, as evidenced by encouraging market research results; and enha...

This article first appeared on GuruFocus. EXPAREL Net Sales: $143.3 million, up from $136.5 million in 2025. ZILRETTA Sales: Increased by 15% to $26.8 million from $23.3 million in 2025. iovera Sales: Increased by 21% to $6.2 million from $5.1 million in 2025. Consolidated Non-GAAP Gross Margin: 80%, compared to 81% last year. Non-GAAP R&D Expense: $25.4 million, up from $23.1 million last year. Non-GAAP SG&A Expense: $83.9 million, compared to $76.2 million last year. Adjusted EBITDA: Approximately $40.2 million for the first quarter. Cash and Investments: $202 million at the end of the quarter. Share Repurchases: $50 million executed, retiring approximately 2.2 million shares. Full-Year Revenue Guidance: $745 million to $770 million. EXPAREL Net Product Sales Guidance: $600 million to $620 million. Non-GAAP Gross Margin Guidance: 77% to 79%. Non-GAAP R&D Expense Guidance: $105 million to $115 million. Non-GAAP SG&A Expense Guidance: $320 million to $340 million. Stock-Based Compensation Guidance: $54 million to $62 million. Depreciation Expense Guidance: Approximately $30 million for 2026. Warning! GuruFocus has detected 9 Warning Signs with PCRX. Is PCRX fairly valued? Test your thesis with our free DCF calculator. Release Date: April 30, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Pacira BioSciences Inc (NASDAQ:PCRX) reported strong first-quarter results, indicating that their 5x30 strategy is delivering intended business results. EXPAREL, the company's flagship product, continues to demonstrate renewed growth, supported by expanded coverage and enhanced intellectual property protection. ZILRETTA and iovera have shown significant sales growth, with ZILRETTA sales increasing by 15% and iovera sales by 21% year-over-year. The company is advancing an innovative clinical stage pipeline, with promising assets like PCRX-201 for knee osteoarthritis and PCRX-2002 for post-surgical pain. Pacira BioSciences Inc (NASDAQ:PCRX) has strong partnerships with companies like Johnson & Johnson MedTech and LG Chem, which are expected to expand their commercial reach and drive revenue growth. First-quarter sales were impacted by winter storms, which disrupted shipping and triggered returns. The company's non-GAAP gross margin slightly decreased to 80% from 81% last year. There is uncertainty regarding the expirat...

Pacira Biosciences (PCRX) reported Q1 non-GAAP earnings late Thursday of $0.60 per diluted share, do

The 'Five by 30' strategy is delivering measurable progress across patients served, product revenue, profitability, pipeline, and partnerships. EXPAREL volume growth is accelerating due to fundamental improvements including NOPAIN Act implementation and a new product-specific J-code for streamlined reimbursement. ZILRETTA and ioverao are benefiting from last year's strategic pivot to dedicated sales forces and expanded promotional reach via the Johnson & Johnson MedTech collaboration. Management has significantly strengthened EXPAREL's intellectual property, expanding from a single litigated patent to 21 Orange Book-listed patents across two families. The company is prioritizing mechanistically de-risked pipeline assets, specifically targeting locally administered therapies that offer superior durability over systemic alternatives. Strategic partnerships, such as those with LG Chem and J&J MedTech, are being utilized to access untapped U.S. and international markets without heavy infrastructure investment. Full-year 2026 revenue guidance is reiterated at $745 million to $770 million, assuming historical quarterly patterns for the remainder of the year. Top-line data readouts for ZILRETTA in shoulder OA and ioverao in spasticity are expected by year-end, potentially opening significant new labeled indications. PCRX201 gene therapy is on track for Phase 2 Part A top-line data later this year, with Part B initiation planned for midyear following manufacturing scale-up. R&D spending is projected to peak in Q2 due to the initiation of PCRX201 Part B and EXPAREL development efforts before declining in the second half. Gross margins are expected to be slightly lower in Q4 due to the sale of higher-cost inventory and planned manufacturing shutdown-related expenses. First quarter EXPAREL revenue growth was partially tempered by a shift in vial mix and increased discounting from a third GPO agreement. Winter storms in Q1 disrupted shipping and triggered product returns, though management believes these impacts are now largely resolved. The company executed $50 million in share repurchases during Q1, retiring 2.2 million shares as part of a disciplined capital return strategy. SG&A expenses in the first half of 2026 are expected to be elevated relative to the second half due to costs associated with proxy-related activities. Our analysts just identified a stock with th...